tiprankstipranks
Trending News
More News >
MindWalk Holdings (HYFT)
NASDAQ:HYFT

MindWalk Holdings (HYFT) AI Stock Analysis

Compare
425 Followers

Top Page

HYFT

MindWalk Holdings

(NASDAQ:HYFT)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 5.2)
Rating:53Neutral
Price Target:
$2.00
▲(11.11% Upside)
The score is held back primarily by weak financial performance (persistent losses and negative cash flows). Offsetting factors include constructive technical trend signals and a positive earnings-call backdrop with strong revenue growth, margin improvement, and a strengthened cash position, while valuation remains challenged due to ongoing losses and no dividend.
Positive Factors
Strong revenue acceleration
Sustained high single-digit to mid-double-digit revenue growth demonstrates durable product-market fit and expanding adoption of subscription and licensing offerings. Over 2–6 months this supports scaling operating leverage, stronger recurring revenue visibility, and a clearer path to absorptive fixed costs.
Material gross margin improvement
A structurally higher gross margin (65%) aligns with a shift to software/AI-enabled offerings (LensAI), indicating more scalable, higher-margin revenue mix. This margin profile supports long-term profitability when coupled with controlled operating expense growth and recurring revenue expansion.
Balance sheet strengthened via divestiture proceeds
One-time divestiture proceeds materially bolstered cash ($16.5M quarter-end), improving runway and funding flexibility. This structural liquidity buffer reduces near-term financing pressure, enabling investment in core AI R&D and partnership formation without immediate dilution.
Negative Factors
Persistent net losses
Ongoing net losses erode shareholder equity and produce negative ROE, signaling the company still needs to translate revenue and gross margin gains into sustainable operating profitability. Continued losses increase the likelihood of future capital raises and constrain strategic optionality.
Negative operating and free cash flows
Structural negative operating and free cash flows indicate the business is burning cash to grow. This makes long-term investment in R&D and commercialization dependent on external financing unless operating cash generation turns positive, raising execution and liquidity risk over the medium term.
Reliance on capital markets for funding
An active ATM agreement signals structural dependence on equity markets to fund growth or cover cash burn. This creates dilution risk for existing shareholders and execution uncertainty if markets tighten, and it implies management may need to access external capital within the next several quarters.

MindWalk Holdings (HYFT) vs. SPDR S&P 500 ETF (SPY)

MindWalk Holdings Business Overview & Revenue Model

Company DescriptionMindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
How the Company Makes MoneyMindWalk Holdings generates revenue through multiple streams, primarily by offering subscription-based services for its mobile applications and online platforms. Users can subscribe to premium features that provide enhanced functionality, personalized insights, and access to exclusive content. Additionally, the company may partner with healthcare providers and organizations to integrate its technology into wellness programs, generating revenue through licensing fees and shared service agreements. Furthermore, MindWalk Holdings could explore partnerships with corporate clients to provide mental health solutions for employee wellness programs, contributing to its earnings through bulk sales and contract agreements.

MindWalk Holdings Earnings Call Summary

Earnings Call Date:Dec 15, 2025
(Q2-2026)
|
% Change Since: |
Next Earnings Date:Mar 18, 2026
Earnings Call Sentiment Positive
The earnings call presents a generally positive outlook for MindWalk, with significant revenue growth, improved gross profit margins, and strategic initiatives like the divestiture of noncore operations and the launch of BioNative AI and HYFT technology. While there are challenges such as operating and net losses, the company's strong cash position and strategic focus on AI-driven R&D suggest a promising future.
Q2-2026 Updates
Positive Updates
Significant Revenue Growth
The company achieved a 54% year-over-year revenue growth and a 30% sequential increase, reaching record quarterly revenue of $4.1 million from continuing operations.
Improved Gross Profit and Margin
Gross profit increased by 94% to $2.7 million with a 65% gross margin, up from 51% in the same period last year.
Strategic Divestiture
The divestiture of noncore wet lab operations in the Netherlands generated approximately $14.3 million in net proceeds, strengthening the balance sheet.
Launch of BioNative AI and HYFT Technology
MindWalk's BioNative AI and patented HYFT technology provide a strategic advantage in AI-driven R&D, supporting programs like GLP1 receptor agonists and dengue vaccine.
Strong Cash Position
The company ended the quarter with $16.5 million in cash, providing flexibility to execute strategic initiatives.
Negative Updates
Operating Loss
Operating loss, excluding amortization and nonrecurring items, was $2.8 million compared to $4.1 million last year.
Net Loss from Continuing Operations
Net loss from continuing operations increased to $3.2 million versus $2.6 million in the same period last year, influenced by divestiture-related impacts.
Company Guidance
During MindWalk's Second Quarter Fiscal 2026 Earnings Call, CEO Dr. Jennifer Bath and CFO Scott Areglado provided robust guidance, highlighting key financial metrics and strategic initiatives. The company achieved a remarkable 54% year-over-year revenue growth, reaching $4.1 million, and a 94% increase in gross profit to $2.7 million, resulting in a 65% gross margin for continuing operations. The divestiture of non-core wet lab operations in the Netherlands generated approximately $14.3 million in net proceeds, strengthening the balance sheet with $16.5 million in cash. Operating expenses for the quarter were $5.4 million, while the operating loss, excluding amortization and nonrecurring items, improved to $2.8 million. Additionally, the company reported an adjusted EBITDA loss of $2.4 million, showcasing improved underlying performance. MindWalk also emphasized its strategic focus on BioNative AI, with its patented HYFT patterns and LensAI platform driving innovations in programs like GLP1 and dengue vaccine initiatives, as well as the establishment of a Cayman Islands-based segregated portfolio structure to facilitate strategic capital partnerships.

MindWalk Holdings Financial Statement Overview

Summary
Revenue is growing, but profitability remains weak with negative net profit/EBIT/EBITDA margins and negative operating/free cash flow. The balance sheet leverage is moderate (debt-to-equity 0.57), but negative ROE reflects ongoing losses.
Income Statement
45
Neutral
MindWalk Holdings shows a positive revenue growth rate of 7.62% TTM, indicating some top-line expansion. However, the company is struggling with profitability, as evidenced by negative net profit, EBIT, and EBITDA margins. The gross profit margin remains relatively stable, but the high negative net profit margin suggests significant challenges in cost management and operational efficiency.
Balance Sheet
50
Neutral
The company's debt-to-equity ratio is moderate at 0.57, indicating a balanced approach to leveraging. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating returns for shareholders. The equity ratio is not explicitly calculated, but the balance sheet suggests a cautious approach to debt, which is a positive aspect.
Cash Flow
40
Negative
Cash flow analysis reveals negative operating and free cash flows, with a slight improvement in free cash flow growth TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and accounting profits, but overall cash flow health remains weak.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue24.31M24.81M21.17M19.80M17.91M
Gross Profit11.50M9.19M7.32M9.17M11.40M
EBITDA-28.89M-23.22M-21.55M-12.27M-4.60M
Net Income-29.97M-26.43M-27.21M-17.09M-7.34M
Balance Sheet
Total Assets44.44M59.99M77.81M93.49M66.96M
Cash, Cash Equivalents and Short-Term Investments10.66M3.46M8.28M29.96M41.76M
Total Debt13.40M13.68M7.27M2.77M3.46M
Total Liabilities20.82M26.07M20.01M18.36M10.04M
Stockholders Equity23.63M33.92M57.80M75.28M56.92M
Cash Flow
Free Cash Flow-7.21M-5.64M-21.33M-11.18M-2.03M
Operating Cash Flow-6.41M-4.25M-19.83M-9.92M-600.00K
Investing Cash Flow-799.00K-1.56M-1.97M-5.21M-2.46M
Financing Cash Flow14.89M1.02M-621.00K2.88M43.38M

MindWalk Holdings Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.80
Price Trends
50DMA
1.97
Negative
100DMA
1.87
Negative
200DMA
1.56
Positive
Market Momentum
MACD
0.02
Positive
RSI
41.21
Neutral
STOCH
33.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYFT, the sentiment is Negative. The current price of 1.8 is below the 20-day moving average (MA) of 2.23, below the 50-day MA of 1.97, and above the 200-day MA of 1.56, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 41.21 is Neutral, neither overbought nor oversold. The STOCH value of 33.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYFT.

MindWalk Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$289.67M-2.18-196.79%37.37%
53
Neutral
$93.85M-3.05-121.76%-17.94%21.43%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
46
Neutral
$64.92M-0.71-51.87%-58.47%
44
Neutral
$34.63M-0.45-122.43%-100.00%-8.30%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYFT
MindWalk Holdings
1.80
1.35
300.00%
XBIT
XBiotech
2.54
-1.08
-29.83%
RLMD
Relmada Therapeutics
3.91
3.56
1017.14%
PMVP
PMV Pharmaceuticals
1.12
-0.32
-22.22%
HOWL
Werewolf Therapeutics
0.72
-0.63
-46.37%
ESLA
Estrella Immunopharma
1.08
-0.04
-3.57%

MindWalk Holdings Corporate Events

MindWalk Holdings Reports Record Growth and Strategic Advances
Dec 15, 2025

On December 15, 2025, MindWalk Holdings reported record financial growth for the second quarter of fiscal 2026, with a 54% increase in revenue and a 94% rise in gross profit year-over-year. The company also announced strategic advancements in its AI asset pipeline, including progress in its GLP1 receptor agonist program and a universal dengue vaccine initiative. MindWalk completed a corporate rebranding, expanded its leadership team, and divested its Netherlands operations to focus on its core BioNative AI initiatives. Additionally, the company is forming a Cayman Islands corporation to house segregated portfolios for its AI-driven programs, allowing direct investor participation. These developments are expected to enhance MindWalk’s industry positioning and operational capabilities.

The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Holdings Emphasizes AI-Driven Strategy in Latest Financial Release
Dec 15, 2025

On December 15, 2025, MindWalk Holdings released its Management Discussion and Analysis for the three and six months ending October 31, 2025. The company is focusing on a software-led model centered on its LensAI platform, which integrates AI and data services for biologics discovery. This strategic shift aims to enhance revenue growth and operational efficiency. The release highlights the company’s efforts in research and development, particularly in dengue and GLP-1 programs, and emphasizes the importance of intellectual property protection. The announcement underscores MindWalk’s commitment to advancing its AI-driven solutions in the drug discovery industry, which may impact its market positioning and stakeholder interests.

The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Holdings Enters Sales Agreement with JonesTrading
Nov 7, 2025

On November 7, 2025, MindWalk Holdings Corp. entered into a Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to offer and sell up to $30 million of its common shares through an ‘at the market offering.’ This strategic move could potentially enhance the company’s financial flexibility and market presence, although there is no obligation to sell shares, and the timing and amount of sales remain uncertain.

The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

MindWalk Holdings Revises Executive Compensation Strategy
Nov 6, 2025

MindWalk Holdings Corp. announced a revised executive compensation statement for the fiscal year ending April 30, 2025, reflecting adjustments made to align with competitive benchmarks. The company’s compensation strategy includes base salaries, short-term cash incentives, and stock options to attract and retain high-quality executives. The adjustments were informed by a benchmarking study conducted by Arnosti Consulting, comparing MindWalk’s compensation with 30 peer companies. The revised compensation plan aims to align executive incentives with long-term company success, focusing on strategic goals such as market engagement and technological integration.

The most recent analyst rating on (HYFT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MindWalk Holdings stock, see the HYFT Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 15, 2026